. Author manuscript; available in PMC: 2017 Jul 7.

Published in final edited form as: NPJ Breast Cancer. 2016 Jan 6;2:15023. doi: 10.1038/npjbcancer.2015.23

Table 1.

Patient and tumor characteristics

Variable	All treated C9741 patients (N =1,972)^a	Subset evaluable by PAM50 (N =1,311)^b	P-value^c
Number of positive nodes; median (IQR)	3 (1, 5)	3 (1, 5)	0.655
Age in years; median (IQR)	50 (43, 57)	50 (43, 57)	0.697
Tumor size
≤ 2 cm	787 (40%)	478 (36%)	< 0.001
> 2 cm	1140 (58%)	803 (61%)
Missing	45 (2%)	30 (2%)
ER status
Positive	1275 (65%)	822 (63%)	0.022
Negative	663 (33%)	468 (36%)
Missing	34 (2%)	21 (1%)
PgR status
Positive	1108 (56%)	706 (54%)	0.008
Negative	821 (42%)	578 (44%)
Missing	43 (2%)	27 (2%)
Menopausal status
Pre	976 (49%)	642 (49%)	0.513
Post	996 (51%)	669 (51%)
Treatment arm
Sequential—q3	483 (25%)	314 (24%)	0.408
Sequential—q2	493 (25%)	343 (26%)
Concurrent—q3	501 (25%)	330 (25%)
Concurrent—q2	495 (25%)	324 (25%)
Recurrence-free survival at
3 years (95% CI)	0.84 (0.82, 0.85)	0.83 (0.81, 0.85)	0.402
5 years (95% CI)	0.77 (0.75, 0.79)	0.76 (0.74, 0.79)
10 years (95% CI)	0.67 (0.65, 0.69)	0.67 (0.64, 0.69)
Overall survival at
3 years (95% CI)	0.92 (0.90, 0.93)	0.91 (0.90, 0.93)	0.403
5 years (95% CI)	0.85 (0.83, 0.86)	0.84 (0.82, 0.86)
10 years (95% CI)	0.72 (0.70, 0.74)	0.72 (0.69, 0.74)

Abbreviations: CI, confidence interval; ER, estrogen receptor; IQR, interquartile range.

N =1,973 patients were reported in the primary manuscript, but one patient was later excluded having never begun treatment.

N =1,311 because 10 patients with PAM50 genomic results never started protocol directed therapy.

P-values are for comparisons of the 1,311 patients evaluable for PAM50 versus the 661 treated patients who were not evaluable. Comparisons for categorical variables use Pearson’s χ² test; for continuous variables use Wilcoxon rank-sum tests; and for time-to-event variables use logrank tests.